Your browser doesn't support javascript.
loading
A Novel Hair Restoration Technology Counteracts Androgenic Hair Loss and Promotes Hair Growth in A Blinded Clinical Trial.
Thor, Dominik; Pagani, Andrea; Bukowiecki, Julia; Houschyar, Khosrow S; Kølle, Stig-Frederik T; Wyles, Saranya P; Duscher, Dominik.
Afiliación
  • Thor D; Tomorrowlabs GmbH, 1010 Vienna, Austria.
  • Pagani A; Department of Orthopedics, Traumatology and Hand Surgery, Hospital of Bolzano-SABES, Lorenz-Böhler-Straße 5, 39100 Bolzano, Italy.
  • Bukowiecki J; Department of Plastic Surgery, SANA Clinic Düsseldorf Gerresheim, Gräulingerstraße 120, 40625 Düsseldorf, Germany.
  • Houschyar KS; Department of Dermatology and Allergology, University Hospital Aachen, 52074 Aachen, Germany.
  • Kølle ST; Department of Plastic Surgery, Cerix Private Hospital, 1150 Copenhagen, Denmark.
  • Wyles SP; Department of Dermatology, Center for Regenerative Biotherapeutics, Mayo Clinic, Rochester, MN 55902, USA.
  • Duscher D; Department of Hand, Plastic, Reconstructive and Burn Surgery, BG-Unfallklinik Tuebingen, University of Tuebingen, Schnarrenbergstraße 95, 72076 Tübingen, Germany.
J Clin Med ; 12(2)2023 Jan 06.
Article en En | MEDLINE | ID: mdl-36675398
ABSTRACT
Androgenic alopecia (AGA) is a genetically predetermined condition that occurs as a result of stepwise miniaturization of the dermal papilla. During this process, the hair follicle suffers from increasing malnutrition and eventually dies, causing progressive hair loss. We recently highlighted that HIF-1α modulation may counteract hair loss. Here, we aim to demonstrate the positive influence of Tomorrowlabs HIF strengthening factor [HSF] hair restoration technology on hair biology in a monocentric blinded clinical trial over a total period of 9 months. A trial with 20 subjects (4 female and 16 male) and once-daily application of [HSF] hair restoration technology to the scalp was conducted. To assess the tolerability and efficacy of [HSF], testing included dermatological assessment, determination of hair loss by counting after combing, macro images of the head and TrichoScan evaluation of hair density as well as the proportion of anagen hair versus telogen hair. The clinical data show Tomorrowlabs [HSF] hair restoration to be safe and effective to counteract AGA. The use of Tomorrowlabs [HSF] hair restoration resulted in improvements in the clinical parameters of hair quality such as thickness (+7.2%), hair density (+14.3%) and shine and elasticity (+20.3%) during the test period. The effectiveness of the test product was further determined by a significant reduction in hair loss of an average of 66.8% in treatment-responsive subjects after 6 months and an increase in hair growth reaching up to 32.5%, with an average percentage change of 8.4% in all participants and 10.8% in the responsive patients (85% of the study cohort) after 9 months on TrichoScan evaluation. The hair growth cycle was harmonized with the result of an average anagen hair percentage increase of +8.0% and telogen hair percentage reduction of -14.0% shown in the test area. Applicable for both sexes in an alcohol-free formulation, beneficial to scalp health and free of complications or side effects, this novel product provides objectively measurable results counteracting hair loss paired with an improved look and feel of the hair.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Clin Med Año: 2023 Tipo del documento: Article País de afiliación: Austria

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Clin Med Año: 2023 Tipo del documento: Article País de afiliación: Austria